Cohort Studyhigh evidence
Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.
JAMA neurology·August 3, 2026·PMID 42545715
Why it mattersCapturing MS progression remains challenging; GFAP offers a blood-based biomarker for risk stratification and monitoring treatment response, potentially improving personalized care and trial efficiency.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled